← ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Pharmaceutical Preparations · market cap $1.5B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
15
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Ascentage Pharma Group International (AAPG) is a clinical-stage oncology-focused pharmaceutical company with 605 employees and a market cap of ~$6.4B at ~$18.9/share. The company fields a broad hematology/oncology pipeline spanning multiple Phase 3 programs, led by Azacitidine Injection for higher-risk MDS, Olverembatinib for GIST, and lisaftoclax combinations in CLL/SLL and AML, with three significant catalysts expected through Q1 2027.
The catalyst path
- 2026-12-15 (est.)Phase 2 · APG2575imp 7/10
- 2026-12-31 (est.)Phase 3 · lisaftoclax +BTK inhibitorimp 9/10
- 2027-03-07 (est.)Phase 2 · Olverembatinibimp 7/10
- 2027-03-31 (est.)Phase 3 · Olverembatinibimp 9/10
- 2027-06-01 (est.)Phase 2 · APG-115imp 7/10
- 2027-06-01 (est.)Phase 2 · APG-2575imp 7/10
- 2027-06-30 (est.)Phase 3 · Bosutinibimp 9/10
- 2027-08-15 (est.)Phase 3 · Acalabrutinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Azacitidine Injection | Phase 3 | Higher-risk Myelodysplastic Syndrome |
| Olverembatinib | Phase 3 | GIST |
| lisaftoclax +BTK inhibitor | Phase 3 | CLL/SLL |
| Lisaftoclax (APG-2575) | Phase 3 | Relapsed/Refractory Acute Myeloid Leukaemia |
| APG-115 | Phase 2 | AML |
| Acalabrutinib | Phase 3 | CLL/SLL |
| Bosutinib | Phase 3 | Chronic Myeloid Leukemia |
| APG-1252 | Phase 2 | NHL, Adult |
| Phase 1b: APG-115+pembrolizumab | Phase 2 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors |
| HQP1351 | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase |
| APG-2575(Lisaftoclax ) | Phase 3 | Acute Myeloid Leukemia |
| APG-1387 for Injection | Phase 2 | Advanced Pancreatic Cancer |
| APG-2575 | Phase 2 | T-Prolymphocytic Leukemia |
| APG2575 | Phase 2 | Chronic Lymphocytic Leukemia |
| Investigator's choice of TKI | Phase 3 | Ph+ ALL |
Price & technical context
3-month
-21.8%
6-month
-44.6%
12-month
-61.7%
52-wk range
$14.86–$40.23
vs 50-day MA
-11.2%
vs 200-day MA
-29.2%
Realized vol
58.7%
Max drawdown
-69.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AAPG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.